Stephen Hahn to be Named FDA Commissioner, says President Trump
In a statement released by The White House today, President Trump announced his plan to nominate Stephen Hahn, M.D. to the position of FDA commissioner. Hahn is a radiation and medical oncologist, and currently serves as the chief medical executive at The University of Texas MD Anderson Cancer Center in Houston.
According to reports, current Acting FDA Commissioner Ned Sharpless will return to his position as director of the National Cancer Institute while HHS official Brett Giroir will step in at FDA until Hahn is confirmed. The Washington Post reports that Sharpless’ term ends Friday, and it could only be extended if the White House named a successor—however, the White House cannot do so because paperwork has not been completed.
Related Articles
-
Califf faced strong opposition but was confirmed in a very close vote.
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.